InvestorsHub Logo
Followers 17
Posts 936
Boards Moderated 0
Alias Born 04/26/2010

Re: loanranger post# 242132

Friday, 09/21/2018 11:30:40 AM

Friday, September 21, 2018 11:30:40 AM

Post# of 403018
No. For BTD FDA does not require the same level clinical proof of efficacy than for marketing approval - I would say 'reasonable' expectation for improvement is enough, especially when there is no approved therapy for the indication. Brilacidin P2 trial does meet that 'standard'. In my opinion even fuzzy results with weekly cisplatin do not warrant rejection of BTD application.

But, FDA is free to disagree. They are also free to ask clarification for any part of application they please. And sometimes they really do please a lot - well beyond being an impartial gatekeeper.


"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News